The final, formatted version of the article will be published soon.You have multiple emails registered with Frontiers:Please enter your email address:

这篇文章的最终格式化版本将很快发布。您在Frontiers注册了多封电子邮件：请输入您的电子邮件地址：

If you already have an account, please

如果您已经有帐户，请

login

登录名

You don't have a Frontiers account ? You can

你没有Frontiers帐户？你可以

register hereBackground: Tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody has been approved in China and Europe. According to the published clinical research, tislelizumab shows satisfactory safety profile. No severe hepatotoxicity or acute kidney injury were reported.Case presentation: We presented a case study of a 74-year-old man who developed acute kidney injury (grade 3) and acute liver injury (grade 4) after being administered tislelizumab for the treatment of esophageal squamous cell carcinoma.

背景：Tislelizumab是一种人源化IgG4抗PD-1单克隆抗体，已在中国和欧洲获得批准。根据已发表的临床研究，tislelizumab显示出令人满意的安全性。没有严重的肝毒性或急性肾损伤的报道。病例介绍：我们介绍了一名74岁男性的病例研究，该男性在服用tislelizumab治疗食管鳞状细胞癌后出现急性肾损伤（3级）和急性肝损伤（4级）。

We reviewed the patient's history, physical examination, and laboratory findings and provided comprehensive differentials of the possible causes of the toxicities.Immune Checkpoint Inhibitors (ICI) hepatotoxicity and nephrotoxicity were confirmed clinically. We also discussed the management of toxicities associated with ICIs and the need for a multidisciplinary approach to care.

我们回顾了患者的病史，体格检查和实验室检查结果，并提供了毒性可能原因的全面差异。临床证实了免疫检查点抑制剂（ICI）的肝毒性和肾毒性。我们还讨论了与ICI相关的毒性管理以及多学科护理方法的必要性。

Conclusions: The case highlights the importance of close monitoring and prompt management of toxicities associated with ICIs and the need for further research to better understand the risk factors for these toxicities and to identify effective treatments for them..

结论：该病例强调了密切监测和及时管理ICI相关毒性的重要性，以及需要进一步研究以更好地了解这些毒性的危险因素并确定有效的治疗方法。。